Cargando…
Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians
BACKGROUND: During the pandemic, there was a dramatic shift to telemedicine for opioid use disorder (OUD) treatment. Little is known about how clinician attitudes about telemedicine use for OUD treatment are evolving or their preferences for future use. OBJECTIVE: To understand OUD clinician views o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038362/ https://www.ncbi.nlm.nih.gov/pubmed/36964424 http://dx.doi.org/10.1007/s11606-023-08165-9 |
_version_ | 1784912063191056384 |
---|---|
author | Huskamp, Haiden A. Riedel, Lauren Campa, Isabella Busch, Alisa B. Rose, Sherri Mehrotra, Ateev Uscher-Pines, Lori |
author_facet | Huskamp, Haiden A. Riedel, Lauren Campa, Isabella Busch, Alisa B. Rose, Sherri Mehrotra, Ateev Uscher-Pines, Lori |
author_sort | Huskamp, Haiden A. |
collection | PubMed |
description | BACKGROUND: During the pandemic, there was a dramatic shift to telemedicine for opioid use disorder (OUD) treatment. Little is known about how clinician attitudes about telemedicine use for OUD treatment are evolving or their preferences for future use. OBJECTIVE: To understand OUD clinician views of and preferences regarding telemedicine. DESIGN: Longitudinal survey (wave 1, December 2020; wave 2, March 2022). SUBJECTS: National sample of 425 clinicians who treat OUD. MAIN MEASURES: Self-reported proportion of OUD visits delivered via telemedicine (actual vs. preferred), comfort in using video visits for OUD, impact of telemedicine on work-related well-being. KEY RESULTS: The mean reported percentage of OUD visits delivered via telemedicine (vs. in person) dropped from 56.9% in December 2020 to 41.5% in March 2022; the mean preferred post-pandemic percentage of OUD visits delivered via telemedicine was 34.8%. Responses about comfort in using video visits for different types of OUD patients remained similar over time despite clinicians having substantially more experience with telemedicine by spring 2022 (e.g., 35.8% vs. 36.0% report being comfortable using video visits for new patients). Almost three-quarters (70.9%) reported that most of their patients preferred to have the majority of their visits via telemedicine, and 76.7% agreed that the option to do video visits helped their patients remain in treatment longer. The majority (58.7%) reported that telemedicine had a positive impact on their work-related well-being, with higher rates of a positive impact among those who completed training more recently (68.5% of those with < 10 years, 62.1% with 10–19 years, and 45.8% with 20 + years, p < 0.001). CONCLUSIONS: While many surveyed OUD clinicians were not comfortable using telemedicine for all types of patients, most wanted telemedicine to account for a substantial fraction of OUD visits, and most believed telemedicine has had positive impacts for themselves and their patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-023-08165-9. |
format | Online Article Text |
id | pubmed-10038362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-100383622023-03-27 Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians Huskamp, Haiden A. Riedel, Lauren Campa, Isabella Busch, Alisa B. Rose, Sherri Mehrotra, Ateev Uscher-Pines, Lori J Gen Intern Med Original Research BACKGROUND: During the pandemic, there was a dramatic shift to telemedicine for opioid use disorder (OUD) treatment. Little is known about how clinician attitudes about telemedicine use for OUD treatment are evolving or their preferences for future use. OBJECTIVE: To understand OUD clinician views of and preferences regarding telemedicine. DESIGN: Longitudinal survey (wave 1, December 2020; wave 2, March 2022). SUBJECTS: National sample of 425 clinicians who treat OUD. MAIN MEASURES: Self-reported proportion of OUD visits delivered via telemedicine (actual vs. preferred), comfort in using video visits for OUD, impact of telemedicine on work-related well-being. KEY RESULTS: The mean reported percentage of OUD visits delivered via telemedicine (vs. in person) dropped from 56.9% in December 2020 to 41.5% in March 2022; the mean preferred post-pandemic percentage of OUD visits delivered via telemedicine was 34.8%. Responses about comfort in using video visits for different types of OUD patients remained similar over time despite clinicians having substantially more experience with telemedicine by spring 2022 (e.g., 35.8% vs. 36.0% report being comfortable using video visits for new patients). Almost three-quarters (70.9%) reported that most of their patients preferred to have the majority of their visits via telemedicine, and 76.7% agreed that the option to do video visits helped their patients remain in treatment longer. The majority (58.7%) reported that telemedicine had a positive impact on their work-related well-being, with higher rates of a positive impact among those who completed training more recently (68.5% of those with < 10 years, 62.1% with 10–19 years, and 45.8% with 20 + years, p < 0.001). CONCLUSIONS: While many surveyed OUD clinicians were not comfortable using telemedicine for all types of patients, most wanted telemedicine to account for a substantial fraction of OUD visits, and most believed telemedicine has had positive impacts for themselves and their patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-023-08165-9. Springer International Publishing 2023-03-24 2023-07 /pmc/articles/PMC10038362/ /pubmed/36964424 http://dx.doi.org/10.1007/s11606-023-08165-9 Text en © The Author(s), under exclusive licence to Society of General Internal Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
spellingShingle | Original Research Huskamp, Haiden A. Riedel, Lauren Campa, Isabella Busch, Alisa B. Rose, Sherri Mehrotra, Ateev Uscher-Pines, Lori Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians |
title | Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians |
title_full | Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians |
title_fullStr | Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians |
title_full_unstemmed | Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians |
title_short | Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians |
title_sort | long-term prospects for telemedicine in opioid use disorder (oud) treatment: results from a longitudinal survey of oud clinicians |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038362/ https://www.ncbi.nlm.nih.gov/pubmed/36964424 http://dx.doi.org/10.1007/s11606-023-08165-9 |
work_keys_str_mv | AT huskamphaidena longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians AT riedellauren longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians AT campaisabella longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians AT buschalisab longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians AT rosesherri longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians AT mehrotraateev longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians AT uscherpineslori longtermprospectsfortelemedicineinopioidusedisorderoudtreatmentresultsfromalongitudinalsurveyofoudclinicians |